HPBCD was found to deliver lanosterol (a tetracyclic triterpenoid) active substance into the crystalline lens of the eye. This delivery system separates the lanosterol molecules from the carriers in the carrier-lanosterol complex attached to the corneal surface, and then quickly passes them through the cornea, anterior, iris and pupil to deliver them into the crystalline lens. Although Lanomax® eye drops were effective also against human catarct, for now a veterinary formulation for dogs and pets is marketed.
The therapeutic effect of Lanomax® varies greatly depending on the type of cataract and the degree of its progression. Generally, in the case of incipient, immature, and mature cataracts, if Lanomax® is administered to both eyes for six weeks (about two bottles), visible improvement is seen compared to untreated eyes before administering Lanomax®. Sometimes there are dramatic cases where a visible effect can even be noticed within a short period of 1-2 weeks after beginning to administer Lanomax®.